Uppsala, Sweden – December 20, 2013 – Orexo AB, “Orexo” (OTCQX: ORXOY; NASDAQ
OMX Stockholm: ORX) announces adjustment to earlier communicated EBIT
expectations for Q4 2013 with continuation of current conservative revenue
recognition practise.

Since launch of Zubsolv® in US, Orexo has supplied US wholesalers with products
at a total value of close to USD 11 million. As the launch of Zubsolv is still
in an early phase, Orexo has decided to continue with its current conservative
revenue recognition practice, which is based on actual patient demand for
Zubsolv, and not switch to a revenue recognition model based on supplies to
wholesaler.

On that basis, only approximately 1/3 of the USD 11 million is expected to be
recognized as gross revenue before rebates and other deductions in 2013. Based
on this, the earlier communicated expectation to deliver a positive EBIT for Q4
is now replaced by an expectation of a negative EBIT of about SEK -30 million
for the quarter.

Zubsolv demand continues the positive week over week volume share growth.
Current market share is now approaching 2% of the buprenorphine/naloxone market
in the US according to Wolters Kluwer statistics.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 18-780 88 00, E-mail: ir@orexo.com

About Orexo AB
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv®, for maintenance
treatment of opioid dependence, in the United States. Zubsolv is a novel
formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and revenue
generating products currently marketed under license in the EU and US. Orexo AB,
with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange,
under the symbol “ORX”, and its American Depositary Receipts (ADRs) trade on the
OTCQX marketplace in the U.S. under the symbol “ORXOY”. The largest shareholders
are Novo A/S and HealthCap.

For information about Orexo AB, please visit www.orexo.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:45 am CET on December 20,
2013.